Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. (clinicaltrials.gov) - Jul 20, 2023 - P2 | N=18 | Completed | Sponsor: Kezar Life Sciences, Inc. | Enrolling by invitation ➔ Completed
Trial completion • Dermatomyositis • Immunology • Myositis
|